TB Resisters Study - DMID 15-0093

Resistance to Latent Mycobacterium Tuberculosis Infection (RL-15)

Information:

DMID Protocol Number: 15-0093

Sponsor - U. S. National Institutes of Health
Principal Investigators – W. Henry Boom, M.D., CWRU; Harriet Mayanja-Kizza, M.B.Ch.B., M.Med., Ph.D., Uganda-CWRU Research Collaboration

Type of Study Prospective Observational Household Contact Study
Design Hybrid Cross-sectional / Cohort Study
Project Site Kampala, Uganda
Population

Ugandan adults, age 15 years or greater, who live in Kampala, Uganda with an individual with active TB disease and do not show signs and symptoms of TB disease themselves

Total participants - 500

Sample Size
  • Infection negative:
  • 250 HHCs who demonstrate no sign of TB infection (not MTB infected, INFneg)  
  • LTBI: 
  • 250 HHCs who demonstrate latent TB infection (LTBI) will be consented and enrolled
Study Period

2015 - Current

Projected time to enroll participants is 4 years. Projected time to complete study is 5 years.  Individual participant duration of follow-up is 12 months after enrollment.

Goal of Study:

The goal of this study is to identify and further define TST/quantiferon concordant TB resister phenotype and their concordant LTBI controls. 

Objectives of Study:

  1. To recruit a new cohort of persons who resist infection with Mycobacterium tuberculosis (MTB) and expand earlier studies on this important phenotype. 

  2. To examine epidemiologic and host genetic, genomic, and immunologic factors associated with the RSTR phenotype.